Dr. Shaf Keshavjee, MD, MSc, FRCSC, FACS
Vice Chair, Senior Scientist, Director, Professor
Vice Chair, Innovation, Dept. of Surgery, University of Toronto, Senior Scientist, Toronto General Research Institute (TGRI), Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre, Professor, Division of Thoracic Surgery & Institute of Biomaterials and Biomedical Engineering, University of Toronto , Scientist, McEwen Centre for Regenerative Medicine, Director, Latner Thoracic Research Laboratories , Medical Director, Surgical Services and Critical Care UHN , Director, Toronto Lung Transplant Program , Surgeon-in-Chief, James Wallace McCutcheon Chair in Surgery
We have developed a technique of lung preservation (LPD solution) that has lead to significant improvements in lung function after transplantation. This solution has now been translated into clinical use in our lung transplant program as well as in transplant programs around the world. We have explored several areas in ischemia reperfusion injury including the role of complement and cytokine related lung injury related to reperfusion. This work is done in cell culture models, rat single lung transplant models and pig single lung transplant models.
Our major project is gene therapy in lung transplantation. We are working on techniques to genetically modify the donor lung so that it is better able to deal with the stress imposed upon it by the transplantation process. We hope to address both ischemia reperfusion injury and obliterative bronchiolitis with gene therapeutic techniques.